Skip to main content
Journal of Vascular Surgery Cases, Innovations and Techniques logoLink to Journal of Vascular Surgery Cases, Innovations and Techniques
. 2025 Dec 6;12(2):102088. doi: 10.1016/j.jvscit.2025.102088

PRKG1 pathogenic variants cause thoracic aortic dissection with minimal aortic dilation: Insights from the UTHealth Houston multidisciplinary aortic and vascular disease conference

Ali Askari a,b, Jennifer R Landes a,b, Alana Cecchi a, Cihan Duran c, Bihong Zhao d, Gustavo S Oderich e, L Maximilian Buja d, Dianna M Milewicz a, Anthony L Estrera e, Rana O Afifi e, Siddharth K Prakash a,b,∗
PMCID: PMC12808876  PMID: 41550994

Abstract

A single, recurrent, gain-of-function pathogenic variant in PRKG1 (p.Arg177Gln, also referred to as p.Arg192Gln) causes heritable thoracic aortic disease with a high lifetime risk for aortic dissections that frequently occur before there is enlargement of the proximal thoracic aorta. This report summarizes the clinical manifestations of the PRKG1 pathogenic variant in two unrelated families, including early-onset type A dissection, chronic thoracoabdominal dissection with visceral complications, and elective aortic repair of the proximal aorta with minimal enlargement. In both families, multiple individuals experienced acute dissections at young ages that led to five fatalities. These cases illustrate the early onset of manifestations of PRKG1-related disease, which are primarily dissections, and underscore the essential role of aggressive gene-based management to prevent dissection in these cases.

Keywords: Heritable thoracic aortic diseases, PRKG1, Thoracic aortic dissection


Heritable thoracic aortic diseases (HTAD) are genetically heterogeneous and can affect multiple vascular beds. Identifying the causative gene in a family with HTAD through genetic testing is critical to optimize surgical and medical management in affected individuals and relatives.1,2 This is especially important in families without syndromic features, including outward physical characteristics, that would otherwise help identify individuals who are at risk for sudden death due to acute aortic dissection.3,4 A multidisciplinary approach to diagnosis and management that draws on the unique perspectives of clinicians and researchers has the potential to significantly improve outcomes. At our institution, a monthly conference was established to review state-of-the-art medical and interventional strategies for complex HTAD cases and formulate individualized care plans. In this series, we highlight conference proceedings in a series of thematically related clinical vignettes.

The 2022 American Heart Association/American College of Cardiology Aortic Disease Guideline includes gene-informed recommendations for the management of HTAD.5 PRKG1 stands out as a unique cause of HTAD due to the fact that a single recurrent pathogenic variant (PV), p.Arg177Gln, confers a high lifetime risk for aortic dissection.4,6 Two-thirds of these dissections are type A (Stanford classification) and the other third are type B dissections, both occurring with normal or mildly dilated aortic diameters. In this report, we present the clinical manifestations, management challenges, and gene-guided interventions of four individuals from two unrelated families with PRKG1-related HTAD. These cases highlight the phenotypic variability and surgical complexity of PRKG1-driven aortopathy and emphasize the role of early genetic diagnosis in guiding clinical decision-making. All patients provided written informed consent to publish their deidentified clinical data as part of research approved by the Committee for the Protection of Human Subjects.

Family 1: Cases 1 and 2

A multigenerational family was first evaluated at our institution in 2012 after the sudden death of a family member at age 35 years due to an acute type A aortic dissection (Fig 1, II:4). His sister, who previously presented with a type B dissection at age 31 years, had undergone genetic testing at that time, which did not identify a PV in any of the known HTAD genes, including TGFBR1, TGFBR2, ACTA2, SMAD3, and COL3A1 (PRKG1 had not yet been identified). In 2013, as part of a research study, exome sequencing identified PRKG1 as the causal gene for HTAD, and the recurrent PV (p.Arg177Gln) was found to be the cause of HTAD in this family.6 Cascade genetic testing confirmed the presence of the PRKG1 PV in six additional family members (Fig 1, III:1, III:2, III:3, III:5, III:6). PRKG1 is now included in all standard commercial aortopathy panels.

Fig 1.

Fig 1

Family I pedigree. The legend indicates the disease and pathogenic variant status of the family members. The age at diagnosis of aortic aneurysm or dissection (“dx”) and age at death (“d”) are shown in years. A diagonal line across a symbol indicates that an individual is deceased.

The experiences of this family reflect early-onset aortic dissections across three generations, which is consistent with the natural history of PRKG1-related aortic dissections with minimal aortic dilations.6 Four affected individuals in this family experienced fatal acute type A aortic dissections: I:2 at age 43 years, II:4 at age 35 years, III:4 at age 23 years, and III:5 at age 18 years. Two other relatives experienced type B aortic dissections: II:2 (proband) at age 31 years and III:2 at age 18 years. Individual III:3 survived a type A dissection at age 24 years and experienced two subsequent type B dissections at ages 25 and 27 years. Individual III:4 presented with a proximal aortic diameter of 3.9 cm at the time of his type A dissection. Notably, his dissection extended into the left common carotid artery. After III:4 was diagnosed, his siblings (III:5 and III:6) were also confirmed to carry the PRKG1 PV and were screened by a pediatric cardiologist. When both were evaluated, their aortic diameters were within normal limits (diameters unspecified), and they were normotensive. A β-blocker medication (metoprolol) was initiated because of the potential to reduce the risk for dissections. Subsequently, III:5 switched from taking metoprolol to an angiotensin receptor blocker (losartan) because of concerns about fatigue. Three months later, III:5 died suddenly at age 18 years from an acute type A aortic dissection.

Case 1

A 16-year-old girl (III:6) with the PRKG1 PV (p.Arg177Gln) was evaluated by the multidisciplinary aortic and vascular team after her brother's (III:5) death at age 18 years due to a type A dissection and was found to have mildly dilated sinuses of Valsalva (3.6 cm, Z = 2.3), left ventricular hypertrophy, and a small atrial septal defect. Other aortic diameters were within normal limits. Considering her family history of aortic dissections at young ages without preceding aortic enlargement, the multidisciplinary care team recommended elective aortic repair of the proximal thoracic aorta. After discussion with the family, the shared decision was to pursue surgery, and she underwent resection and replacement of the sinuses, ascending aorta, and proximal arch with aortic valve repair and reimplantation of the right and left coronary arteries. Her surgical team noted that the aortic tissues were extremely thin, almost translucent, and required smaller than usual sutures. The surgeon also commented on the unique challenges of positioning the coronary buttons within the relatively small confines of the nondilated aortic sinuses.

Histological evaluation of the aortic tissue demonstrated multifocal disruption of elastic fibers, vacuolar degeneration of smooth muscle cells, and accumulation of mucoid extracellular matrix material, indicative of moderate medial degeneration (Fig 2). The patient recovered uneventfully and was discharged home on postoperative day 8. Follow-up images disclosed no residual aortic disease.

Fig 2.

Fig 2

Histopathological findings in case 1. A, Transmural section of aorta stained for elastic tissue shows the adventitia (A), media (M), and intimal surface devoid of atherosclerotic change. Elastic tissue stain shows multiple foci of elastic fiber loss in the media (stars). B, At higher magnification, elastic tissue stain shows multiple areas of attenuation and loss of elastic fibers (stars). C, The media also has focal regions where smooth muscle nuclei are lost (arrow) and adjacent smooth muscle cells exhibit vacuolar degeneration (star), as shown in this section stained with hematoxylin and eosin (H&E). D, Smooth muscle cells with vacuolar degeneration (arrows) are shown at higher magnification in this H&E-stained section. Magnification bars are shown on the photomicrographs.

Case 2

A 27-year-old man (III:3) with PRKG1 PV, who was a first cousin of III:4 (case 1), was initially evaluated at age 20 years when he developed chest pain while weightlifting and was found to have a thoracic aortic aneurysm with a maximum diameter of 4.0 cm at the sinuses of Valsalva. His affected mother had survived a type B aortic dissection at age 31 years, and his half-brother (III:2) reported chest pain during exercise and was diagnosed with an acute type B dissection at age 18 years. At age 22 years, he was normotensive but began to take losartan preventatively and was counseled to avoid strenuous exertion.

At age 24 years, he presented with an acute type A aortic dissection and underwent an emergent Bentall procedure at an outside hospital with replacement of the proximal aorta and implantation of a mechanical St Jude aortic valve prosthesis. At age 25 years, he was hospitalized with a new, uncomplicated type B dissection. Images showed that the largest diameter of the thoracic aorta at that time was 3.0 cm (Fig 3). He was discharged without any intervention after his symptoms completely resolved. At age 27 years, he developed recurrent chest pain while lifting heavy weights against medical advice. The computed tomography angiography (CTA) demonstrated a new focal arch dissection and a second type B dissection with a new intimal flap that originated at the left subclavian artery and extended to the right renal artery (Fig 4). In total, the patient was hospitalized three times for thoracoabdominal dissections. His symptoms resolved after intensification of his medical therapies with escalating doses of losartan and metoprolol, and his dissected aortic segments did not dilate under continued close surveillance.

Fig 3.

Fig 3

Axial computed tomography angiography (CTA) image of the chest demonstrating type B aortic dissection. A, The dissection flap is noted in the proximal descending thoracic aorta (red arrow). B, No dissection flap in the aortic arch.

Fig 4.

Fig 4

Computed tomography angiography of the thoracic aorta. (A and B) Three-dimensional, volume-rendered reconstructions and (C) sagittal angiographic image demonstrate chronic type B dissection and moderate dilation of the descending aorta.

Family 2: Cases 3 and 4

Case 3

The PRKG1 p.Arg177Gln PV was identified in another unrelated family who was referred to our research program to identify novel genes for HTAD. Several individuals who experienced aortic dissections in this family were not diagnosed with thoracic aortic enlargement before the dissections (Fig 5). The proband II:6 was evaluated because of a significant family history of aortic disease. His brother had a type B aortic dissection at age 51 years, which was the first confirmed aortic event in 2005. His eldest daughter (III:1) died from a peripartum type A aortic dissection at age 27 years in 2006, and his father had died suddenly at age 47 years. The 67-year-old male proband (II:6) with the PRKG1 PV was first evaluated in person at our center in October 2012 after the PRKG1 p.Arg177Gln PV was identified in him. He was asymptomatic and had no personal history of cardiovascular disease. A CTA and transthoracic echocardiography revealed a proximal aortic aneurysm measuring 4.6 cm. In October 2012, he underwent valve-sparing (David procedure) replacement of the sinuses, ascending aorta, and proximal transverse arch. The PRKG1 p.Arg177Gln PV was confirmed in his brother, who had experienced a type B dissection, and two of his daughters through cascade genetic testing.

Fig 5.

Fig 5

Family pedigree. The legend indicates the disease and pathogenic variant status of the family members. The age at diagnosis of aortic aneurysm or dissection (“dx”) and age at death (“d”) are shown in years. A diagonal line across a symbol indicates that an individual is deceased.

After surgical repair, he was initiated on medical therapy with the β-blocker nebivolol, which was subsequently escalated to a multidrug regimen of losartan, nebivolol, and nifedipine. Over the next decade, he remained asymptomatic with well-controlled blood pressure (systolic 100-120 mm Hg, diastolic 60-70 mm Hg) and heart rates in the range 60-69 beats. Annual surveillance imaging demonstrated stable postoperative anatomy. An echocardiogram in January 2022 confirmed a preserved left ventricular ejection fraction of >60% and trace aortic insufficiency, whereas CTA in March 2022 showed no progression of thoracoabdominal aortic disease.

Twelve years after his initial operation in November 2024, he presented again with chest pain and was diagnosed with an acute type B aortic dissection. An emergent CTA demonstrated that the proximal descending thoracic aorta had enlarged from 4.2 cm to 4.6 cm over the previous 6 months. In January 2025, he underwent a redo sternotomy with transverse arch replacement, bypass grafts to the innominate and left carotid arteries, and a frozen elephant trunk procedure with a hybrid branched graft. At the time of surgery, the proximal descending thoracic aorta had further dilated to 4.9 cm (Fig 6). He recovered uneventfully and was transitioned postoperatively to metoprolol succinate 25 mg daily. At his recent follow-up visit, he remained asymptomatic and normotensive with no detectable aortic changes on surveillance CTA images.

Fig 6.

Fig 6

Representative computed tomography angiography (CTA) images of this patient include three-dimensional reconstructed aortic models at three time points: (A) preoperative acute type B dissection (November 2024), (B) immediate postoperative frozen elephant trunk repair (January 2025), and (C) stent extending to the proximal abdominal aorta.

Case 4

We evaluated the oldest daughter (Fig 5, III:3) of the proband in family 2 when she was 40 years old. At the time of her acute type A dissection at age 27 years, her proximal aorta was reported to be normal in diameter (3.4 cm). She underwent emergent mechanical Bentall with replacement of her sinuses and ascending aorta. Four years later, in 2016, a surveillance CTA revealed a chronic aortic dissection extending from the distal end of the surgical graft to the infrarenal abdominal aorta. All visceral vessels originated from the true lumen. The descending thoracic aorta was mildly dilated (3.4 cm). Over 9 years of subsequent annual surveillance, her aortic anatomy remained stable without detectable dilation. Medications were titrated during this period from an initial daily regimen of spironolactone 25 mg and metoprolol 25 mg to metoprolol succinate 50 mg and losartan 25 mg in 2025. She is adherent to therapy, normotensive, and remains asymptomatic on follow-up.

In contrast, her younger sister (III:4) did not have detectable aortic disease at age 38 years. A chest magnetic resonance angiography in January 2015 demonstrated normal thoracoabdominal aortic diameters with the sinuses measuring 3.3 cm and the ascending aorta measuring 2.9 cm, unchanged from prior studies. Subsequent surveillance images in 2016 and 2024 confirmed the stability of the proximal aorta at 3.1-3.3 cm and no dilation of the thoracoabdominal aorta. However, a new dissection of the proximal right subclavian artery was identified in 2016 and increased in diameter from 1.6 cm at the time of discovery to 1.9 cm in February 2025. Her initial daily antihypertensive regimen of atenolol 25 mg, spironolactone 25 mg, and lisinopril 2.5 mg was intensified to atenolol 37.5 mg and losartan 25 mg in 2025. She has never been hypertensive, remains clinically well, and continues annual surveillance.

Discussion

The PRKG1 PV p.Arg177Gln (p.Arg192Gln) is estimated to account for less than 1% of all nonsyndromic HTAD cases.7,8 PRKG1 encodes a cyclic guanosine monophosphate-dependent-dependent protein kinase that regulates smooth muscle relaxation and vasodilation.9 PRKG1 p.Arg177Gln is a gain-of-function variant that causes constitutive activation of the kinase, resulting in decreased vascular smooth muscle cell contractility.7 Individuals with this variant are highly likely to experience an aortic dissection during their lifetimes,6 with a cumulative incidence of 86% (95% CI: 69%-96%) by age 65 years.4 These vignettes highlight the aggressive but variable course of PRKG1-related aortopathy, which is primarily characterized by presentation with type A or type B aortic dissections at normal aortic diameters or diameters that are well below conventional surgical thresholds. The disease affects both the ascending and descending aorta as well as supra-aortic branch vessels, underscoring the systemic nature of PRKG1-mediated vascular pathology.

The 18-year-old brother of case 1 (III:5) died from an acute type A dissection after stopping metoprolol and initiating losartan. Randomized trials and an individual patient-level meta-analysis in Marfan syndrome show that angiotensin receptor blockers, such as losartan, are as effective as β-blockers in reducing aortic dilation and do not detectably increase the risk for aortic dissection.10,11 Current guidelines for HTAD endorse either agent interchangeably (or frequently in combination) at maximally tolerated doses.5 It is notable that β-blocker withdrawal is biologically plausible as a trigger for an acute aortic dissection via sympathetic rebound causing tachycardia and hypertension to acutely raise aortic wall stress.12 This is a recognized complication linking an acute dissection to β-blocker discontinuation.13,14 Applied to PRKG1 aortopathy, which can cause dissections at relatively small aortic diameters, the sequence of β-blocker cessation followed by initiation of losartan may have contributed to the acute dissection of III:5. This case emphasizes the need for research to identify the most appropriate medical therapies for PRKG1 aortopathy while also emphasizing the lack of drugs that prevent aortic dissection.

Current clinical guidelines recommend that patients with sporadic sinus and ascending aneurysms should be referred for surgical repair when aortic diameters exceed ≥5.5 cm, but allow for earlier repair if other risk factors, such as a family history of dissection, rapid aortic dilation, or when a causative HTAD PV is identified.15 For HTAD genes, the aortic diameter for proximal aortic surgery varies based on the causative gene. For example, patients with a TGFBR1 or TGFBR2 PV are recommended to undergo surgical repair when aortic diameters exceed 4.5 cm, and 4.0 if high-risk features for an aortic dissection are present.15 There are limited data on the optimal timing of elective repair of PRKG1-associated HTAD. Because of the frequency of early dissections in PRKG1 families, the 2022 guidelines recommended a lower surgical threshold for PRKG1 of 4.2 cm or even 4.0 cm in the presence of additional risk factors, such as a family history of aortic dissection at normal aortic diameters or aortic dilation exceeding 0.3 cm in 1 year.6,8,16 However, the clinical course of PRKG1-related HTAD is highly variable, as illustrated by the divergent experiences of the sisters in vignette 4. One sister (III:3) developed an extensive DeBakey type I chronic dissection extending into the visceral arteries, whereas the other sister (III:4) maintained normal aortic diameters but developed a dissection and subsequent aneurysm of the right subclavian artery. Therefore, vigilant lifelong surveillance is essential for PRKG1 PV carriers, even when they appear to be clinically stable. These vignettes illustrate the potential value of a multidisciplinary approach with shared decision-making for preventative interventions in PRKG1-related HTAD.

Survival analysis shows that aortic dissections frequently precede the diagnosis of aneurysms in PRKG1 patients, necessitating preventative aortic repair when the aorta is mildly dilated or even normal in size.15,17,18 Baseline imaging of the thoracic aorta is recommended at the initial visit. If the ascending aorta is not adequately visualized with a transthoracic echocardiogram, then magnetic resonance imaging or computed tomography of the chest is recommended to determine the optimal surveillance and therapeutic approach.15 All first-degree relatives of the proband should promptly receive cascade genetic testing, and affected individuals should take β-blockers, even if they do not have hypertension.6 Early detection and surveillance are essential to prevent deaths due to dissections.8,15

Conclusions

These cases underscore the critical role of a genetic diagnosis in guiding management for individuals with PRKG1-related HTAD. In this series, recognition of the PV not only directed care for the probands but also justified preemptive aortic repair in an at-risk relative who did not have an aneurysm, highlighting how genetic risk alone may warrant surgical intervention. A proactive surgical strategy is particularly reasonable in PRKG1-related HTAD, given that the PRKG1 PV is associated with dissections as young as 17 years of age, two-thirds of which are type A and frequently fatal. Accordingly, the discussion of these risks with affected families is essential, and elective repair of a normal proximal aorta before age 18 years may be appropriate. Because individuals with the PRKG1 PV also appear to be vulnerable to type B dissections, comprehensive management should include initiation of β-blocker therapy with counseling against abrupt discontinuation and lifelong imaging surveillance. Together, these data support an individualized but assertive approach to prevention and ongoing monitoring of PRKG1 aortopathy.

Funding

These studies were funded by NIH R01HL109942, the Genetic Aortic Disorders Association Canada, the Remebrin’ Benjamin Fund, and the John Ritter Foundation.

Data availability statement

All data available on request from the corresponding author.

Disclosures

A.L.E. is on the advisory board of Artivion and a consultant for WL Gore and Terumo Aortic. The remaining authors report no conflicts.

Footnotes

The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

References

  • 1.Coady M.A., Davies R.R., Roberts M., et al. Familial patterns of thoracic aortic aneurysms. Arch Surg. 1999;134:361–367. doi: 10.1001/archsurg.134.4.361. [DOI] [PubMed] [Google Scholar]
  • 2.Biddinger A., Rocklin M., Coselli J., Milewicz D.M. Familial thoracic aortic dilatations and dissections: a case control study. J Vasc Surg. 1997;25:506–511. doi: 10.1016/s0741-5214(97)70261-1. [DOI] [PubMed] [Google Scholar]
  • 3.Renard M., Francis C., Ghosh R., et al. Clinical validity of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol. 2018;72:605–615. doi: 10.1016/j.jacc.2018.04.089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Regalado E.S., Morris S.A., Braverman A.C., et al. Comparative risks of initial aortic events associated with genetic thoracic aortic disease. J Am Coll Cardiol. 2022;80:857–869. doi: 10.1016/j.jacc.2022.05.054. [DOI] [PubMed] [Google Scholar]
  • 5.Writing Committee Members, Isselbacher E.M., Preventza O., Black J.H., III, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. J Thorac Cardiovasc Surg. 2023;166:e182–e331. doi: 10.1016/j.jtcvs.2023.04.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Guo D chuan, Regalado E., Casteel D.E., et al. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet. 2013;93:398–404. doi: 10.1016/j.ajhg.2013.06.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Encica S., Molnar A., Manole S., et al. Rare causes of arterial hypertension and thoracic aortic aneurysms-A case-based review. Diagn Basel Switz. 2021;11:446. doi: 10.3390/diagnostics11030446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Shalhub S., Regalado E.S., Guo D.C., Milewicz D.M., Montalcino Aortic Consortium The natural history of type B aortic dissection in patients with PRKG1 mutation c.530G>A (p.Arg177Gln) J Vasc Surg. 2019;70:718–723. doi: 10.1016/j.jvs.2018.12.032. [DOI] [PubMed] [Google Scholar]
  • 9.Milewicz D.M., Trybus K.M., Guo D.C., et al. Altered smooth muscle cell force generation as a driver of thoracic aortic aneurysms and dissections. Arterioscler Thromb Vasc Biol. 2017;37:26–34. doi: 10.1161/ATVBAHA.116.303229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lacro R.V., Dietz H.C., Sleeper L.A., et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014;371:2061–2071. doi: 10.1056/NEJMoa1404731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Pitcher A., Spata E., Emberson J., et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022;400:822–831. doi: 10.1016/S0140-6736(22)01534-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Karachalios G.N., Charalabopoulos A., Papalimneou V., et al. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract. 2005;59:562–570. doi: 10.1111/j.1368-5031.2005.00520.x. [DOI] [PubMed] [Google Scholar]
  • 13.Koracevic G., Micic S., Stojanovic M., et al. Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies. Hypertens Res. 2020;43:591–596. doi: 10.1038/s41440-020-0449-6. [DOI] [PubMed] [Google Scholar]
  • 14.Eber B., Tscheliessnigg K.H., Anelli-Monti M., et al. Aortic dissection due to discontinuation of beta-blocker therapy. Cardiology. 1993;83:128–131. doi: 10.1159/000175959. [DOI] [PubMed] [Google Scholar]
  • 15.Isselbacher E.M., Preventza O., Black J.H., et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 2022;146:e334–e482. doi: 10.1161/CIR.0000000000001106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gago-Díaz M., Blanco-Verea A., Teixidó G., et al. PRKG1 and genetic diagnosis of early-onset thoracic aortic disease. Eur J Clin Invest. 2016;46:787–794. doi: 10.1111/eci.12662. [DOI] [PubMed] [Google Scholar]
  • 17.Saeyeldin A., Zafar M.A., Li Y., et al. Decision-making algorithm for ascending aortic aneurysm: effectiveness in clinical application? J Thorac Cardiovasc Surg. 2019;157:1733–1745. doi: 10.1016/j.jtcvs.2018.09.124. [DOI] [PubMed] [Google Scholar]
  • 18.Bisleri G. Commentary: timing for aortic surgery in rare genetic variants: when prevention warrants intervention? J Thorac Cardiovasc Surg. 2019;157:e111–e112. doi: 10.1016/j.jtcvs.2018.10.022. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data available on request from the corresponding author.


Articles from Journal of Vascular Surgery Cases, Innovations and Techniques are provided here courtesy of Elsevier

RESOURCES